Functionally defective high-density lipoproteins are related to heightened T-cell activation in vertically HIV-infected adolescents

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 3, 2014, Pages 265-269

  Sainz, Talía ^a   Ortega Hernández, Adriana ^b   Serrano Villar, Sergio ^c   Navarro, María L ^d   Rojo, Pablo ^e   Ramos, José T ^f   Mellado, María J ^g   Diaz, Laura ^a   Alvarez, Maria ^a   Estrada, Vicente ^b   Gómez Garre, Dulcenombre ^b   Muñoz Fernández, María A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Adolescents; CRP; HDL dysfunction; HIV; Immune activation; IMT; Vertical transmission

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; C REACTIVE PROTEIN; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOPINAVIR PLUS RITONAVIR;

ADOLESCENT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VERTICAL TRANSMISSION; VIRUS LOAD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPLICATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY;

ADOLESCENT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CHEMOTAXIS; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS, HDL; LYMPHOCYTE ACTIVATION; MALE; MONOCYTES; T-LYMPHOCYTES; VIRAL LOAD;

EID: 84899039378     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000160     Document Type: Article

References (15)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
2. Hsue P, Deeks SG, Hunt P. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205(suppl):S375-S382.
3. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011;203:452-463.
4. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
5. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268-273.
6. Feldman JG, Goldwasser P, Holman S, et al. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003;32:210-214.
7. Rose H, Woolley I, Hoy J, et al. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism. 2006;55:90-95.
8. Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;181(suppl):S462-S472.
9. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
10. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001;103:2283-2288.
11. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199:79-86.
12. Khera AV, Cuchel M, De La Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
13. Sainz T, Alvarez-Fuente M, Navarro ML, et al. Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study. J Acquir Immune Defic Syndr. 2014;65:42-49.
14. Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation. 2005;112:103-109.
15. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.